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Abstract: Cisplatin must be considered the treatment standard for
lung cancer chemotherapy, whatever the disease setting, at least in
the Western world. After the seminal meta-analysis published in
1995, 12 randomized clinical trials (RCTs) exploring the benefits of
adjuvant cisplatin-based chemotherapy have been completed, pub-
lished, or presented. Although all these RCTs differ in patient
features, two common suggestions emerge when the stage is taken
into account: a significant benefit for chemotherapy is demonstrated
for stage II and IIIA patients and none of these trials showed any
significant benefit for adjuvant chemotherapy in stage IB patients.
Ten years after this meta-analysis, a further individual patient
data-pooled analysis exploring the eventual benefits of adjuvant
cisplatin-based chemotherapy after surgery for early stage non-small
cell lung cancer in the more recent RCTs has been presented. The
5-year overall survival benefit in favor of cisplatin-based chemo-
therapy was 5.3% (48.8% versus 43.3%, p  0.004), with a relative
risk reduction of 11%. These results confirm those reported by
previous meta-analyses performed according to a literature-based
approach. Advances are emerging in the selection of those patients
who are likely to benefit more from such treatment. In this respect,
the customized therapy based on molecular/genetic patient and
disease features constitutes a new avenue to pursue.
(J Thorac Oncol. 2007;2: Suppl 1, 7–11)
Lung cancer is the leading cancer death cause in men in theUnited States.1,2 Almost 80% of all lung cancers are
defined as non-small cell lung cancer (NSCLC).2,3 Despite
the recent advances in both screening and imaging tools,
NSCLC is still diagnosed at local or more often distant
advanced stage, whereas relatively few tumors (approxi-
mately 30%) are present at an early stage.3 Surgery has to be
considered the standard of treatment for early-stage disease,
although many stage II and III patients will progress within
few months after tumor resection.3 Given the high incidence
and mortality, this disease is considered a social illness in the
Western countries, and for this reason, several screening
programs have been established with the intent to resect as
many patients as possible at earlier stages. Despite the con-
cern over the interpretation of such randomized clinical trials
(RCTs), advances in this field have been made recently.4 In
the past 15 years, large RCTs have been conducted to see
whether adjuvant radiotherapy, chemotherapy, or both are
able to improve local control and survival after surgery, with
conflicting results. Two large meta-analyses have shed light
on the existing literature of the 1990s by ruling out any
supposed survival advantage for adjuvant radiotherapy (along-
side specific techniques, doses, and tools) and conferring a
slightly better survival trend for patients receiving adjuvant
chemotherapy, although not statistically significant (p 
0.08).5,6 Actually, improved locoregional control for patients
receiving adjuvant radiotherapy was documented in that
meta-analysis accruing more than 2000 patients.5 These data
suggested that death from lung cancer could be attributed to
distant, extrathoracic metastases and that chemotherapy
would work in adjuvant setting as demonstrated for advanced
disease in at least two meta-analyses.6,7 While in the ad-
vanced setting, the benefit of chemotherapy is to date well
established regardless of other important prognostic factors
such as performance status, its blind application for whatever
stage resected NSCLC patients is still under debate. The
positive trend that emerged in the Lung Cancer Collaborative
Group (LCCG) meta-analysis in this merged population al-
lowed the start of further adjuvant RCTs specifically designed
to detect the observed benefits of the previous meta-analysis,6
in some cases in a larger patient cohort.8–11
RCTs EXPLORING ADJUVANT CHEMOTHERAPY
The LCCG clearly established that (1) in advanced
disease, cisplatin-based chemotherapy significantly improved
survival versus supportive care (p  0.0001); (2) cisplatin-
based chemotherapy significantly improved outcome when
associated with exclusive radiotherapy for locally advanced
disease (p  0.005); (3) a strong trend in favor of adjuvant
cisplatin-based chemotherapy after surgery was documented
(p  0.08), whereas a significant detrimental negative effect
against long-term adjuvant alkylating agents was present
(p  0.005).6 Because of this evidence, cisplatin has
become the treatment standard for NSCLC chemotherapy
in both clinical research and daily practice, at least in the
Western countries.
After the LCCG meta-analysis, 12 RCTs exploring the
benefit of adjuvant cisplatin-based chemotherapy have been
completed, published, or presented6,8–19; one of the earliest
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(which started accrual before the Post-Operative Radio-
Therapy meta-analysis came out) randomized stage II to III
NSCLC patients to radiotherapy after surgery versus radio-
therapy plus chemotherapy after surgery.10 Only one of these
RCTs has not yet been published.15 With a median follow-up
ranging from 44 to 91 months, six RCTs demonstrated a
significant survival benefit for patients receiving chemother-
apy.8,11,12,14,18,19 If we consider only those RCTs with an
almost adequate patient sample, the International Adjuvant
Lung Cancer Trial (IALT) provided the first substantial
evidence that adjuvant cisplatin-based chemotherapy would
be beneficial for patients who had undergone surgery for
stage I to III NSCLC.8
Although the previous Adjuvant Lung Cancer Project
Italy/European Organization for Research and Treatment of
Cancer Lung Cancer Cooperative Group trial showed no
significant benefits for the experimental arm, in that study,
survival for stage II patients receiving chemotherapy was
shown to be better than that for those without treatment.9 The
most important contribution to this topic was provided by six
RCTs, whose characteristics are listed in Table 1; different
patient characteristics are present across all RCTs, in partic-
ular in staging, pneumonectomy, and radiotherapy rate.
In all these trials, cisplatin was the lead drug, with the
exception of the Cancer and Leukemia Group B (CALGB)
9633 protocol, which included the carboplatin-paclitaxel dou-
blet.15 This trial was started after 1996, at a time when there
was not so much evidence to suggest that this combination
was equally efficient for cisplatin-based doublets.20,21 The
earliest presentation of the CALGB 9633 trial provided a
significant survival benefit for the chemotherapy arm, but a
later update demonstrated no significant differences between
the two arms.15
Despite the differences of all these RCTs in patient
features, two common considerations emerge when the stage
is taken into account: (1) none of the trials showed any
significant benefit for adjuvant chemotherapy in stage IB
patients8,9,11,15,18 and (2) a significant benefit of chemotherapy
is demonstrated for stage II9,11,18 and IIIA8,11 patients.
META-ANALYSES EXPLORING ADJUVANT
CHEMOTHERAPY FOR NSCLC
The first results of the Lung Adjuvant Cisplatin Eval-
uation (LACE) pooled analysis exploring the eventual benefit
of adjuvant cisplatin-based chemotherapy after surgery for
early-stage NSCLC were presented at the last American
Society of Clinical Oncology (ASCO) meeting.22 This was
the first individual patient data meta-analysis after the semi-
nal LCCG meta-analysis, which actually changed the treat-
ment guidelines for NSCLC after 19956; therefore, these
updated results have been awaited worldwide from more than
10 years. The authors chose 300 patients per trial as cutoff for
entry into the analysis, so they correctly called it a pooled
analysis instead of meta-analysis. Although 300 patients per
trial are unlikely to be sufficient to determine significant
survival advantage in adjuvant NSCLC, it allowed those trials
that were certainly underpowered to be ruled out. Indeed, a
meta-analysis should comprehensively include all RCTs spe-
cifically designed to answer the question that the analysis is
requested to explore.23 Although apparently it seems formal,
this is a fundamental issue when considering the increasing
number of published and presented meta- and pooled analy-
ses. With regard to the strict criteria according to which a
high-quality meta-analysis should be designed, the LACE
authors did not choose the chemotherapy benefit as the main
endpoint, but the “identification of trials or patient character-
istics associated with the benefit of adjuvant cisplatin-based
chemotherapy for NSCLC.”22 Five RCTs with 4584 patients
were included,8,9,11,17,18 and the 5-year overall survival ben-
efit in favor of cisplatin-based chemotherapy was 5.3%
(48.8% versus 43.3%), with a relative risk reduction of 11%
(hazard ratio  0.89, 95% confidence interval: 0.82–0.96,
p  0.004), with no significant heterogeneity (p  0.34)
(Table 2). The characteristics of RCTs and patients that
seemed to be associated with the benefit of chemotherapy
were age, sex, performance status, type of surgery, histology,
stage, drug administered with cisplatin, radiotherapy and
overall cisplatin dose. Unfortunately, only few of these re-
sults have been presented in detail. Although subgroup anal-
ysis can be dangerous and easily misunderstood, given the
pr-specified intent provided by the authors when the analysis
started, the risk seems to have been avoided in this case.24
The combination of cisplatin and vinorelbine seemed to be
the most active among all the adopted schedules. Actually,
these results may have been biased by the fact that this is the
most studied combination (1888 patients), and, above all, the
TABLE 1. Adjuvant Randomized Clinical Trial
Characteristics
Author
No.
of Pts.
Pneumonectomy
(%)
Stage
I/II/III (%) RT (%)
Arriagada et al.8 1867 35 37/24/39 30
Scagliotti et al.9 1209 25 39/33/28 43
Winton et al.18 482 23 45/55/— —
Waller et al.17 381 — 27/38/34 14
Douillard et al.11 840 37 35/30/35 25
Strauss et al.15a 344 10 —/100/— —
a Only in abstract form. pts., patients; RT, radiotherapy.
TABLE 2. LACE Meta-analysis Results22
Subgroup No. of Patients HR (95% CI)
OS
Overall analysis 4584 0.89 (0.82–0.96)
CDDP  vinorelbine 1888 0.80 (0.70–0.91)
Stage IA 347 1.41 (0.96–2.09)
Stage IB 1371 0.92 (0.78–1.10)
Stage II 1616 0.83 (0.73–0.95)
Stage III 1247 0.83 (0.73–0.95)
DFS
Overall analysis 4584 0.84 (0.78–0.90)
HR, hazard ratio; CI, confidence intervals; OS, overall survival; CDDP, cisplatin;
DFS, disease-free survival.
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cisplatin dose combined with vinorelbine is significantly
higher than with other drugs. From this perspective, we are
unable to understand whether the benefit is due to vinorel-
bine, to the higher cisplatin dose, or both, also taking into
account that this should be considered a post hoc analysis. In
advanced disease, the cisplatin dose (and dose intensity)
seems to play an important role in improving outcome.25 The
stage analysis confirms the data coming from both RCTs and
a previous meta-analysis, i.e., chemotherapy significantly
works in stages II and III, with no impact on stage IB (Table
2).26 In particular, the best approach for stage IB patients is an
intriguing issue. The update of the CALGB 9633 released at
the last ASCO annual meeting did not confirm the positive
survival improvement in favor of the adjuvant carboplatin-
paclitaxel arm as documented at the ASCO presentation in
2004.15 Moreover, although a significant advantage in dis-
ease-free survival in favor of chemotherapy was confirmed at
the last follow-up, the interpretation of this endpoint in this
setting, and actually in this disease, is not yet clear. The
LACE authors concluded that (1) cisplatin-based adjuvant
chemotherapy significantly improves overall and disease-free
survival in patients who have undergone surgery for NSCLC;
(2) the most active combination seems to be cisplatin (at the
total dose of 320–400 mg/m2) plus vinorelbine); (3) adjuvant
chemotherapy certainly provides benefit for stage II and III
patients, and this benefit is independent of other prognostic
factors. Although the multivariate analysis was not able to
distinguish between the independent role of the cisplatin dose
and the associated drug, the overall conclusions are not that
different from those reported by four other literature-based
meta-analyses that were published recently, as shown in
Table 3.27–30 As shared worldwide, according to the National
Cancer Institute recommendation, levels for data transfer
from clinical research to clinical practice, quality- and meth-
odology-controlled meta-analyses (together with large RCTs)
provide strong evidence.31 Although individual patient data
meta-analyses are considered the favorite way of collecting
and summarizing the results of RCTs, the above-mentioned
literature-based meta-analyses produced a homogeneous ben-
efit in favor of adjuvant chemotherapy, with an absolute
benefit ranging from 2% to 4.5%, whichever population was
explored (Table 3). Even considering the subgroup analyses
(although taking into account all the limitations and risks of
this approach24), the literature-based meta-analyses demon-
strated almost the very same results as the LACE.26
INTERPRETATION OF CLINICAL RESEARCH DATA
When trying to interpret these RCTs, many issues are
still open that concern (1) applied methodology of each single
trial; (2) subgroup analyses; (3) drugs used, doses, and dose
intensities; (4) accrual rate and time frame; (5) overall treat-
ment duration; (6) adjunct radiotherapy. Many of the RCTs
underwent protocol revisions of the expected hazard ratios
(and patient sample size) during enrollment (Table 4), and
this can be considered a bias. Furthermore, the randomized
patients per year/enrollment time ratio was too low in some
trials, rendering the daily clinical reproducibility too far from
clinical practice. Indeed, one of the largest trials that yielded
a benefit with cisplatin-vinorelbine in stage II and IIIA
patients had a relevant slow recruitment bias.11 Moreover, it
appears that the benefit of adjuvant chemotherapy tends to be
small (approximately 2%–4%), whatever the patient sample
and regimen. Although this translates into thousands of saved
lives, given the social impact of this disease, treatment costs
and toxicities (including toxic deaths) should be taken into
account. Therefore, methodological issues and compliance
with chemotherapy need to be carefully weighted when trying
to interpret these RCTs (Table 2). If the positive survival
results provided by the single RCTs are confirmed by the
forthcoming individual patient data meta-analysis update, we
should conclude that chemotherapy has an impact on the
natural history of NSCLC. Actually, we are unable to under-
stand to what extent the greater benefit coming from some
specific stage and trial has contributed to the general result.
Even if the data coming from subgroup analyses of the
RCTs8,11 have been confirmed by the LACE meta-analysis22
(i.e., stage II–III, performance status 0–1), we are still debat-
ing whether any conclusion is widely applicable or is just a
hypothesis-generating exercise.24,32 It is certain that the par-
adigm in the treatment of early-stage NSCLC has shifted in
the past 3 years; the positive results of RCTs accruing more
than 7000 patients and the meta-analyses performed offered
promising results in favor of adjuvant chemotherapy. Ad-
vances are emerging about the selection of those patients who
are likely to better benefit from such treatment. From another
point of view, when looking at the adjuvant scenario in other
tumors, an absolute increase of 4% to 8% in 5-year survival
provided by chemotherapy in breast or colon cancer has been
TABLE 3. Overview of All Meta-analyses Exploring Adjuvant
Chemotherapy
Meta-Analysis No. of Patients HR (95% CI)
LCCG6 1394 0.87 (0.74–1.02)
Pignon et al.22 4584 0.89 (0.82–0.96)
Hotta et al.27 3786 0.89 (0.81–0.97)
Sedrakyan et al.28 3518 0.89 (0.82–0.96)
Berghmans et al.29 4602 0.83 (0.80–0.92)
Bria et al.30 7334 0.93 (0.88–0.97)
HR, hazard ratio; CI, confidence intervals; LCCG, Lung Cancer Collaborative
Group.
TABLE 4. Difference between Planned and Obtained
Survival Benefit across RCTs
Author
Required
Sample
Size
Planned No. of
Courses/
Compliance
OS % Gain
Planned Obtained
Arriagada et al.8a 3300 3–4/74% 5% (5 yr) 4% (5 yr)
Scagliotti et al.9 1300 3/69% 7% (5 yr) 3% (5 yr)
Winton et al.18 450 3–4/65% 10% (3 yr) 15% (3 yr)
Waller et al.17 4000 3/64% 5% (5 yr) 0 (1 yr)
Douillard et al.11 800 4/76% 10% (2 yr) 5.1% (2 yr)
Strauss et al.15b 384 4/85% NR 12% (4 yr)
a Change in trial design.
b Only in abstract form.
Pts., patients; OS, overall survival; NR, not reported.
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considered worldwide sufficient to transfer the treatment into
daily clinical practice. In a disease such as NSCLC, an
absolute survival benefit of 2% to 4% at 5 years should be the
best realistic goal, as suggested 10 years ago by the LCCG
meta-analysis and confirmed by the more recent RCTs and
meta-analyses.8,11,22,27–30
FUTURE PERSPECTIVES: CUSTOMIZED
CHEMOTHERAPY
The role of customized therapy in adjuvant setting is
now even more appealing than a few years ago. In particular,
a number of studies have proved the relevance of predicting
outcome of several genes involved in chemotherapy-induced
DNA damage. Indeed, given that worldwide, and especially
in European countries, cisplatin-based chemotherapy remains
the gold standard in the treatment of NSCLC, several more
new data have been published recently about the correlation
of specific DNA repair gene expression and survival benefit
of cisplatin-based chemotherapy. The NER system is the
major mechanism of repair of DNA adducts induced by
cisplatin33; this is constituted by a series of proteins, of which
ERCC1 is suggested as a surrogate marker of the entire
system. Several studies have analyzed the expression (mea-
sured as quantitative expression by real-time PCR [RT-PCR])
of ERCC1 in the metastatic setting of patients affected by
esophageal, gastric, and pulmonary cancer.34–36 In these ret-
rospective studies, ERCC1 has demonstrated a predictive role
in the benefit of a cisplatin-based chemotherapy in terms of
response and/or survival. Very recently, the French group that
conducted the IALT study published the results of the anal-
ysis of ERCC1 expression (by immunohistochemistry) and its
correlation with outcome in approximately 40% of patients
treated with cisplatin-based chemotherapy.37 This retrospec-
tive analysis was able to demonstrate a significant statistical
impact of no ERCC1 expression and better survival as proven
by a 35% reduction in the risk of death in the group of
patients who received adjuvant chemotherapy (versus those
who did not). Based on the seminal results of the predictive
role of ERCC1, a prospective study in metastatic NSCLC was
conducted by the Spanish Lung Cancer Group and presented
at the European Society for Medical Oncology meeting.
Patients were randomized to standard chemotherapy or cus-
tomized chemotherapy based on ERCC1 expression levels.
Patients receiving customized treatment had a significantly
better response. For the first time in the adjuvant setting and
in a large group of patients, these findings shed light on
NSCLC treatment. Pharmacogenomics could help clinicians
in decision making. In fact, the use of adjuvant chemotherapy
has not been established for all stages or for all patients.
Moreover, bio-IALT suggests a possible large-scale applica-
tion of this method by using immunohistochemistry. This
could mean fast confirmation in a prospective study and
easier training. These results should encourage us to improve
research in this field, but they also act as a caveat: when we
are facing potential markers, we need to globalize/universal-
ize the method and render it reproducible. If not, it is
advisable to leave its use to skilled researchers. Because all
previous studies have retrospectively analyzed the role of
ERCC1 by RT-PCR, is important to define the role of both
methods described so far. RT-PCR is more capable of defin-
ing the scale, more than a black or white expression. This
could imply the introduction of different chemotherapy
agents, including the newest ones.
CONCLUSIONS
More than 10 years after the publication of the seminal
LCCG meta-analysis that first defined the treatment guide-
lines to be adopted for patients with NSCLC, we now have
sufficient evidence from both RCTs and meta-analyses to
recommend adjuvant cisplatin-based chemotherapy for stage
II to III patients. This treatment suggestion should be clearly
discussed with the patients, taking both toxicities and costs
into account. More RCTs specifically addressed for stage IB
and elderly patients are needed. The relatively small absolute
benefits (together with the high toxicity) strongly suggest
selecting patients based on findings that are different from the
clinical factors. In this respect, the customized therapy based
on molecular/genetic patient and disease features constitutes
a new avenue to pursue.
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